NEW YORK: In the aftermath of the pharmaceutical company Eli Lilly’s announcement that their drug Solanezumab may actually inhibit memory loss in people with Alzheimer’s, several authoritative scientists called for more testing, and it seems that there may be contention on what constitutes an effectual test population.
Researchers have widely acknowledged the benefits of Solanezumab, since it is literally the first drug to have proved to actually slow the effects of Alzheimer’s disease on the brain. Many other scientists, however, contest these findings, claiming that Solanezumab was only tested on individuals who had already manifested symptoms of Alzheimer’s and therefore have already shown decreased brain function. Currently, scientists are trying to get Eli Lilly to come up with a way to develop the drug such that it helps those already predisposed to the disease…